Drawing for THERA NEUROPHARMA

USPTO serial 87021064

THERA NEUROPHARMA

Reviewed by CopyMark Law Group

Status 606
Filing date
Status date
Registration date
—
Examiner
CHADAB, SETH WILLIG
Law office
INTENT TO USE SECTION

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with THERA NEUROPHARMA?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Sherry Flax

SHERRY FLAX SAUL EWING LLP500 E. PRATT ST.SUITE 900BALTIMORE, MD 21202

Goods and services

ClassDescriptionStatusFirst use
005Biological preparations for the treatment of central nervous system and neurological conditions and disorders; Pharmaceutical preparations acting on the central nervous system; Pharmaceutical preparations for the treatment of central nervous systems and neurological conditions and disorders; Pharmaceutical preparations for central nervous system and neurological conditions and disorders; Pharmaceutical preparations acting on the central nervous systemACTIVE—
042Pharmaceutical product evaluation; Pharmaceutical products development; Pharmaceutical research services; Research and development and consultation related thereto in the field of pharmaceuticals; Research and development in the pharmaceutical and biotechnology fields; Research in the field of central nervous system and neurological conditions and disorders; Consulting services in the fields of biotechnology, pharmaceutical research and development and genetic science; Laboratory research in the field of central nervous system and neurological conditions and disorders; Medical laboratory services; Scientific research for medical purposes in the field of pharmaceuticals for the diagnosis and treatment of central nervous systems and neurological conditions and disorders; Scientific research in the field of pharmaceuticals; Technical consulting in the field of pharmaceutical studiesACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

Latest event (MAB6): The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.

DateCodeEventWhat it means
Jul 9, 2018MAB6ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Jul 9, 2018ABN6ABANDONMENT - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Jan 16, 2018EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Jan 14, 2018EX1GSOU EXTENSION 1 GRANTED—
Jan 14, 2018AITUCASE ASSIGNED TO INTENT TO USE PARALEGAL—
Dec 8, 2017NREVNOTICE OF REVIVAL - E-MAILED—
Dec 7, 2017TPEXSOU EXTENSION RECEIVED WITH TEAS PETITION—
Dec 7, 2017PETGPETITION TO REVIVE-GRANTED—
Dec 7, 2017PROATEAS PETITION TO REVIVE RECEIVED—
Dec 6, 2017EXT1SOU EXTENSION 1 FILED—
Jun 6, 2017NOAMNOA E-MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
Apr 11, 2017NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Apr 11, 2017PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Mar 22, 2017NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Mar 2, 2017CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Feb 16, 2017TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Feb 15, 2017CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Feb 15, 2017TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Aug 24, 2016GPRNNOTIFICATION OF PRIORITY ACTION E-MAILEDA priority action is a type of Office Action the USPTO treats as time-sensitive. It usually means the examining attorney needs a specific response or amendment quickly — often relating to a foreign priority claim or a formal requirement. Respond within the stated deadline.
Aug 24, 2016GPRAPRIORITY ACTION E-MAILEDA priority action is a type of Office Action the USPTO treats as time-sensitive. It usually means the examining attorney needs a specific response or amendment quickly — often relating to a foreign priority claim or a formal requirement. Respond within the stated deadline.
Aug 24, 2016CPRAPRIORITY ACTION WRITTENA priority action is a type of Office Action the USPTO treats as time-sensitive. It usually means the examining attorney needs a specific response or amendment quickly — often relating to a foreign priority claim or a formal requirement. Respond within the stated deadline.
Aug 17, 2016DOCKASSIGNED TO EXAMINER—
May 5, 2016NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
May 5, 2016NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance